AR039546A1 - Terapia de reemplazo hormonal - Google Patents

Terapia de reemplazo hormonal

Info

Publication number
AR039546A1
AR039546A1 ARP030101718A ARP030101718A AR039546A1 AR 039546 A1 AR039546 A1 AR 039546A1 AR P030101718 A ARP030101718 A AR P030101718A AR P030101718 A ARP030101718 A AR P030101718A AR 039546 A1 AR039546 A1 AR 039546A1
Authority
AR
Argentina
Prior art keywords
days
treatment cycle
phase
conjugated estrogens
replacement therapy
Prior art date
Application number
ARP030101718A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29550090&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR039546(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR039546A1 publication Critical patent/AR039546A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)

Abstract

Reivindicación 1: Un método para el tratamiento o la inhibición de trastornos menopáusicos o posmenopáusicos en una mujer perimenopáusica, menopáusica o posmenopáusica que lo necesita, que comprende proporcionar oralmente a dicha mujer, en forma continua y sin interrupciones durante 28 días en un ciclo de tratamiento de 28 días, una primera fase de una posología diaria de 0,625 mg de estrógenos conjugados, en la que se proporciona la misma posología de estrógenos conjugados por 10-18 días del ciclo de tratamiento, empezando el día 1 del ciclo de tratamiento y una segunda fase de una combinación de una posología diaria de 0,625 mg de estrógenos conjugados y 0,0625 a 0,25 mg de trimegestona, en la que se proporciona la misma posología de la combinación de 10-18 días del ciclo de tratamiento, empezando el día siguiente al termino de la primera fase.
ARP030101718A 2002-05-17 2003-05-16 Terapia de reemplazo hormonal AR039546A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38125702P 2002-05-17 2002-05-17

Publications (1)

Publication Number Publication Date
AR039546A1 true AR039546A1 (es) 2005-02-23

Family

ID=29550090

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101718A AR039546A1 (es) 2002-05-17 2003-05-16 Terapia de reemplazo hormonal

Country Status (11)

Country Link
US (1) US20030216367A1 (es)
EP (1) EP1507539A1 (es)
JP (1) JP2005530791A (es)
CN (1) CN1668310A (es)
AR (1) AR039546A1 (es)
AU (1) AU2003234579A1 (es)
BR (1) BR0310085A (es)
CA (1) CA2484646A1 (es)
MX (1) MXPA04011258A (es)
TW (1) TW200400040A (es)
WO (1) WO2003097071A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004275470B2 (en) * 2003-09-29 2010-12-02 Novo Nordisk Health Care Ag Improved stability of progestogen formulations
DK1670440T3 (da) * 2003-09-29 2014-07-07 Novo Nordisk As HRT formuleringer
CA2569738A1 (en) * 2004-06-07 2005-12-22 Duramed Pharmaceuticals, Inc. Dispenser for progestin used for acute and maintenance treatment of dub
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
US8217024B2 (en) * 2005-12-27 2012-07-10 Teva Women's Health, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
JP5193196B2 (ja) 2006-06-02 2013-05-08 ペア ツリー ウーマンズ ヘルス ケア 萎縮性膣炎の治療の方法
ES2669694T3 (es) * 2009-10-19 2018-05-28 The Population Council, Inc. Neuroprotección y reparación de mielina usando Nestorone®
US9446051B2 (en) 2009-10-19 2016-09-20 The Population Council, Inc. Neuroprotection and myelin repair using nestorone®
CA2836388A1 (en) * 2012-12-21 2014-06-21 The Population Council, Inc. Neuroprotection and myelin repair using st-1435
DE102019115343A1 (de) * 2019-06-06 2020-12-10 EVESTRA GmbH Vaginalring für die hormonelle Kontrazeption

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
FR2692267B1 (fr) * 1992-06-11 1995-05-19 Roussel Uclaf Nouveau procédé de préparation de composés stéroïdes 20-céto 21alpha-hydroxy et intermédiaires.
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5759577A (en) * 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
US5547948A (en) * 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
DE19503160A1 (de) * 1995-02-01 1996-08-08 Bayer Ag Verwendung von Phenylcyclohexylcarbonsäureamiden
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
AU2092300A (en) * 1999-01-18 2000-08-01 Novo Nordisk A/S Use of estrogens and delta-gonadien-21-ol-3,20-diones in the treatment or prophylaxis of cerebral degenerative disorders
FR2801218B1 (fr) * 1999-11-23 2001-12-28 Hoechst Marion Roussel Inc Compositions pharmaceutiques comprenant de la trimegestone, leurs procedes de preparation ainsi que le conditionnement primaire les renfermant
US20010034340A1 (en) * 2000-03-20 2001-10-25 American Home Products Corporation Hormone replacement therapy
TW200306851A (en) * 2002-04-29 2003-12-01 Wyeth Corp Hormone replacement therapy

Also Published As

Publication number Publication date
WO2003097071A1 (en) 2003-11-27
CA2484646A1 (en) 2003-11-27
TW200400040A (en) 2004-01-01
MXPA04011258A (es) 2005-01-25
JP2005530791A (ja) 2005-10-13
CN1668310A (zh) 2005-09-14
EP1507539A1 (en) 2005-02-23
US20030216367A1 (en) 2003-11-20
AU2003234579A1 (en) 2003-12-02
BR0310085A (pt) 2005-02-15

Similar Documents

Publication Publication Date Title
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
AR039546A1 (es) Terapia de reemplazo hormonal
AR024566A1 (es) Administracion de esteroides androgenicos no orales a mujeres
ECSP088123A (es) Anticoncepcion oral con trimegestona
EA200201000A1 (ru) Гормон-заместительная терапия
ES2196303T3 (es) Administracion de nicotina por el colon para tratar enfermedades intestinales inflamatorias.
AR051931A1 (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclos extendidos con dosis ascendentes
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
UY26977A1 (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgésicos
TR200002207T1 (tr) Slekoksib bileşikleri.
HN1999000015A (es) Tratamiento para una disfuncion sexual femenina
HUP9901360A2 (hu) Cimicifuga racemosa-ból származó extraktum alkalmazása
AR033042A1 (es) Terapia de reemplazo hormonal
HUP0102913A2 (hu) Biogén ösztrogén-szulfamátok alkalmazása hormonhelyettesítő terápiánál használható gyógyszerkészítmények előállítására
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
AR039547A1 (es) Terapia de reemplazo hormonal
CR8010A (es) Regimenes de contraceptivos transdermicos extendidos
CO5190674A1 (es) Tratamiento de desordenes neuroticos desordenes neuroticos
AR049196A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
DE60026491D1 (de) Melagatran zur behandlung von entzündungen
PE20031047A1 (es) Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama
TR200200978T2 (tr) Yeni mirtazapin formülasyonu
BR0309032A (pt) Método para tratar sintomas vasomotores, a menopausa, deficiências hormonais em um paciente, e para tratar um paciente que sofre de sintomas vasomotores
GEP201606538B (en) Preoperative treatment of post operative pain
AR049195A1 (es) Uso de una combinacion de etinilestradiol y acetato de clormadinona para la preparacion de un medicamento

Legal Events

Date Code Title Description
FB Suspension of granting procedure